Who will be the winner(s)? How will later entrants differentiate? Interesting to see how the space of obesity is getting even more crowded with Pfizer's big bet. Weight loss alone can no longer be the driving force alone for a late entrant. Tolerability, monthly dosing vs. weekly (U.S. payers' not always loving that) etc. to come, and obviously the comorbidity play (e.g. cardio-metabolic) which is also the focus of other Big Pharma players who has been in it for a lot longer, like Novo Nordisk and Eli Lilly, the two dominant players in this space. Check out the analyst deck from Pfizer regarding the Metsera acquisition, if you are interested in this space. https://lnkd.in/emZSKNFF

🚨 M&A Update: Pfizer announces the acquisition of Metsera, strengthening its position in obesity and cardiometabolic diseases with a portfolio of promising clinical-stage assets. We are exposed to Metsera through our Obesity Solutions strategy ➡️ https://lnkd.in/eyVQNXJN #acquisition #obesitysolutions #marketingcommunication

Pipeline, Patients, and Pricing: Lessons from Pfizer’s Latest Acquisition #MarketAccess #PharmaNews #ObesityTreatment #PricingAndReimbursement #PharmaStrategy #PipelineInnovation #PatientAccess #Pharmaceuticals #GlobalHealth #Pfizer #Metsera #HealthcareInnovation Pfizer has announced its acquisition of Metsera, a clinical-stage company advancing therapies for obesity and cardiometabolic diseases. The deal is valued at approximately $4.9 billion upfront, with an additional $2.4 billion in potential milestone payments — bringing the total to $7.3 billion. From a market access perspective, this acquisition is noteworthy: Pipeline potential: Metsera’s candidates, including GLP-1 receptor agonists and monthly amylin analogs, could reshape obesity treatment by improving efficacy, safety, and patient adherence. Competitive positioning: Pfizer strengthens its position against leaders like Novo Nordisk and Eli Lilly, while highlighting the importance of innovative dosing strategies in chronic disease management. Access implications: Successful commercialization will depend on regulatory approvals, pricing, and reimbursement strategies across markets — areas where early planning can make a big difference. This deal reinforces a key lesson I’ve seen throughout my career in market access: strategic acquisitions are as much about science as they are about understanding patient needs, regulatory pathways, and reimbursement landscapes.

Exciting news for medical fraternities: Merck Completes Acquisition of Verona Pharma Acquisition strengthens Merck’s cardio-pulmonary portfolio with addition of Ohtuvayre® (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade. Through this acquisition Merck has added Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline and portfolio. The U.S. Food and Drug Administration approved Ohtuvayre in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years and combines bronchodilator and non-steroidal anti-inflammatory effects. Ohtuvayre is also being evaluated in clinical trials for the treatment of non-cystic fibrosis bronchiectasis. #medicine #pharma #pharmaceutical #patient #medical #socialmedia #business

EFPIA - European Federation of Pharmaceutical Industries and Associations publishes report on "Future-Proofing the Alzheimer’s Disease Healthcare Journey: Emerging Best Practices Across Europe" https://lnkd.in/eFUTUf3W

We’re pleased to announce the expansion of our strategic partnership with Civica, Inc., to increase access to affordable medicines for U.S. patients with diabetes.  The multi-year transformational agreement between Biocon Biologics and Civica Rx creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin medicine to Civica, and Civica will commercialize under Biocon Biologics’ existing marketing approval (a private label agreement). Civica will distribute, promote, and sell the medicine in the United States under a separate Civica label and trade dress, and in California, the product will carry the CalRx brand. Biocon Biologics will continue to directly commercialize Biocon Biologics’ own Insulin medicine, which was approved by the U.S. Food and Drug Administration (FDA) in July 2021 as the first interchangeable biosimilar. We are building on our differentiated approach to serving and enhancing patient access—by retaining our direct commercialization and through this strategic partnership, enabling us to reach underserved populations through new channels in direct alignment with our mission. This collaboration builds on our ongoing work with Civica and reflects our commitment to partnering with healthcare stakeholders to increase the supply of high-quality, affordable treatment options to patients who need them.  #BioconBiologics #Civica #AccessToCare #Partnership

I'm proud to share that Biocon Biologics is expanding our strategic partnership with Civica, Inc. to increase access to affordable diabetes treatments. This demonstrates the strength of the Biocon Biologics platform — our ability to commercialize effectively and partner with organizations like Civica to expand insulin access and reach more patients in need.  #BioconBiologics #Diabetes #Partnership #AccessToCare 

Happy Monday! More biotech + pharma updates below: 🤝 Cidara Therapeutics lands up to $339M Biomedical Advanced Research and Development Authority (BARDA) contract for non-vaccine flu prevention ✅ Ovid Therapeutics reports positive Ph1 data in drug-resistant epilepsy 🏭 FDA launches generics priority review program for domestic manufacturing 📰 GSK comes out on top in UK Prescription Medicines Code of Practice Authority marketing scuffle 💰 Palisade Bio closes $138M public offering fuelling IBD ambitions For a the full picture, see today's TLDR Biotech newsletter for free here: https://lnkd.in/gqZaTbsJ ---------------------------------------- One skimmable email per day to keep up with biotech and pharma ➡️ https://lnkd.in/gh68uhTQ

🩸Biocon Biologics & Civica Rx join hands to expand affordable insulin access in the U.S. Big news in diabetes care — Biocon Biologics has expanded its partnership with Civica Rx to launch a private-label Insulin Glargine for the U.S. market. With 38.4 million Americans living with diabetes and nearly a quarter undiagnosed, this collaboration brings much-needed affordable options to patients. Under this deal, Biocon Biologics will manufacture Insulin Glargine while Civica Rx commercializes it under its own label (CalRx in California). Biocon Biologics already supplies over 9.2 billion doses of insulin globally, and this move strengthens its mission to make high-quality biosimilars accessible to all. A powerful example of collaboration driving affordability and impact in healthcare. Follow Harshal Jain for the latest insights into the healthcare world! #PharmaNews #PharmaStrategy #IndianPharma #PharmaUpdates #Harshal #PharmawithHJ #HJ